US FDA Vaccines Adcomm May Be Called To Review COVID-19 Vaccine Strain Changes

 
• By Derrick Gingery

CBER Director Peter Marks said the VRBPAC may need to opine on the immunogenicity data gathered for vaccine updates.

CBER's Peter Marks is interviewed in his basement for the FDA/CMS Summit 2020. (screenshot)
Peter Marks said that the source of anaphylactic reactions to the vaccines still is unknown, but studies are ongoing. • Source: Screenshot

More from Vaccines

More from Pink Sheet